Drug Profile
Schisandrin B
Alternative Names: (-) schisandrin B; Sch BLatest Information Update: 16 Oct 2012
Price :
$50
*
At a glance
- Originator Hong Kong University of Science and Technology; MitoPharm Corporation
- Developer MitoPharm Corporation
- Class
- Mechanism of Action Antioxidants; Mitochondrial protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Reperfusion injury
Most Recent Events
- 16 Oct 2012 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
- 16 Oct 2012 Discontinued - Preclinical for Reperfusion injury in USA (unspecified route)
- 22 Jun 2007 Preclinical trials in Reperfusion injury in USA (unspecified route)